WO1986006368A1 - Stereoselective process and chiral intermediates for aryloxydropanolamines - Google Patents

Stereoselective process and chiral intermediates for aryloxydropanolamines Download PDF

Info

Publication number
WO1986006368A1
WO1986006368A1 PCT/GB1985/000514 GB8500514W WO8606368A1 WO 1986006368 A1 WO1986006368 A1 WO 1986006368A1 GB 8500514 W GB8500514 W GB 8500514W WO 8606368 A1 WO8606368 A1 WO 8606368A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
isomer
optionally substituted
alkyl
Prior art date
Application number
PCT/GB1985/000514
Other languages
French (fr)
Inventor
Michael Barry Mitchell
John Kitteringham
Original Assignee
Smith Kline & French Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline & French Laboratories Limited filed Critical Smith Kline & French Laboratories Limited
Priority to AT85905641T priority Critical patent/ATE40548T1/en
Priority to DE8585905641T priority patent/DE3568040D1/en
Publication of WO1986006368A1 publication Critical patent/WO1986006368A1/en
Priority to DK619886A priority patent/DK619886D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton

Definitions

  • the present invention relates to a general method for preparing chiral ⁇ -adrenoceptor antagonists and to intermediates therefor.
  • ⁇ -Adrenoceptor antagonists are useful in the treatment of a range of diseases for example hypertension, angina, myocardial infarction, arrhythmias, thyrotoxicosis, anxiety, migraine, tremor, glaucoma and congestive heart failure.
  • ⁇ -adrenoceptor antagonists have the general formula (I) :-
  • Ar is an optionally substituted aryl, heteroaryl or heterocyclic group as known in the art
  • R is an optionally substituted alkyl group as known in the art for example a group R 2 R 3 CH- as hereinafter defined.
  • the carbon atom bearing the hydroxy group is chiral and it is generally acknowledged that ⁇ -adrenoceptor activity resides in the S-isomer.
  • S-isomers are prepared by resolution or by asymmetric synthesis.
  • these processes are difficult and inefficient and, in general, S-isomers of ⁇ -adrenoceptor antagonists substantially free of the corresponding R-isomer have not been widely commercialised.
  • R is as hereinbefore defined, by reaction with benzaldehyde and modification of the terminal hydroxy group to introduce the -O-Ar group.
  • the present invention provides the S-isomer of a compound of the formula (IV) :
  • Ar is an optionally substituted aryl, heteroaryl or heterocyclic group, and R is phenyl optionally substituted by C 1-6 alkoxy or C 1-6 alkyl.
  • Ar is an optionally substituted aryl, heteroaryl or heterocyclic group as known in the ⁇ -adrenoceptor antagonist art.
  • Ar is phenyl optionally substituted by one, two or three groups selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkanoyl, C 1-6 alkanoyloxy, C 2-6 alkenyl, C 2-6 alkenyloxy, C 3-10 cycloalkyl, halo, carbamoyl, C 1-6 alkylcarbamoyl, di-C 1-6 alkylcarbamoyl, arylcarbamoyl, arylC 1-6 alkyl, arylC 1-6 alkoxy, C 1-6 alkanoylamino, arylC 1-6 alkanoylamino, arylC 1-6 alkanoyl, arylC 2-6 alkenyl, carbamoylC 1-6 alkyl, C 1-6 alkylcarbamoylC 1-6 alkyl, di-C 1-6 alkylcarbamoylC 1-6 alkyl, arylC 2
  • Ar is indanyl, indenyl, naphthyl, 5-oxotetrahydronaphthyl, 6-oxotetrahydronaphthyl, tetrahydronaphthyl, 5,8-dihydronaphthyl or 7 ,8-dihydroxytetrahydronaphthyl.
  • Ar is an optionally substituted heteroaryl or heterocyclic group suitably it contains up to three heteroatoms selected from oxygen, sulphur and nitrogen.
  • pyridinyl, pyrimidinyl, quinolinyl, indolyl, and 1,2,5-thiadiazol-3-yl are those described hereinabove as suitable for substitution on phenyl.
  • groups Ar are 2-cyanophenyl, 2-methylphenyl, 2,3-dimethylphenyl, 4-(2-methoxyethyl)phenyl, 4-(carbamoylmethyl)phenyl, 2-allyloxy, 4-butyronamidophenyl, 2-chlorophenyl, 2-methoxyphenyl, 2-morpholinophenyl, 4-(2-(cyclopropylmethoxy)ethyl)phenyl, 4-methanesulphonamidophenyl, 4-(2-acetylethyl)phenyl, 4-morpholino1,2,5-thiadiazol-3-yl, 4-acetamidophenyl and phenyl.
  • R 1 is phenyl or phenyl substituted by one, two or three groups selected from C 1-6 alkoxy and C 1-6 alkyl, for example methylphenyl, methoxyphenyl and ethoxyphenyl.
  • R 1 is phenyl.
  • the compounds of the formula (IV) are useful in that they can be converted to the S-isomers of a wide range of ⁇ -adrenoceptor antagonists in two steps.
  • the present invention provides a process for preparing the S-isomer of a compound of the formula (V) :
  • R 1 and Ar are as hereinbefore defined, and R 2 R 3 CH- represents optionally substituted alkyl: which process comprises reacting the S-isomer of a compound of the formula (IV) as hereinbefore defined with a compound of the formula (VI) , or a compound of the formula (VIA) under conditions of reductive alkylation :
  • R 2 and R 3 are as hereinbefore defined and X is a displaceable group.
  • the present invention provides the S-isomer of a compound of the formula (V) .
  • Suitable and preferred values for R 1 and Ar are as described for compounds of the formula (IV) .
  • R 2 R 3 CH- is a moiety known in the ⁇ -adrenoceptor antagonist art, for example R 2 is hydrogen or C 1-6 alkyl, preferably hydrogen or methyl, and R 3 is optionally substituted C 1-6 alkyl.
  • Suitable substituents for R 3 include those of the following sub-formulae:
  • R a is C 1-6 alkyl, phenyl or phenylC 1-6 alkyl, said phenyl groups being optionally substituted by one, two or three groups as defined hereinabove with reference to suitable substituents for Ar; and R b is hydrogen or C 1-6 alkyl.
  • R 2 R 3 CH- is isopropyl.
  • X is halo, for example chloro or bromo. Conveniently the reaction is performed in a substantially inert solvent.
  • reaction between compounds of the formulae (IV) and (VIA) is performed under conventional reductive alkylation conditions, for example in a substantially inert solvent in the presence of Raney nickel.
  • the present invention provides a process for the preparation of the S-isomer of a compound of the formula (VII) :
  • R 2 , R 3 and Ar are as hereinbefore defined, which comprises reducing the S-isomer of a compound of the formula (V) as hereinbefore defined.
  • the reduction is performed using catalytic hydrogenation in conventional manner.
  • conventional transition metal catalysts such as palladium on a suitable carrier with hydrogen gas or under conditions of catalytic transfer hydrogenation.
  • palladium on carbon and palladium hydroxide on carbon may be used.
  • Hydrogenation with hydrogen gas may be performed at non-extreme pressure for example between atmospheric pressure and pressures of 10 atmospheres.
  • hydrogenation is performed in a C 1-4 alkanol for example ethanol.
  • Catalytic transfer hydrogenation can be effected for example using hydrazine.
  • R 1 and Ar are as hereinbefore defined, and A' is an acid-cleavable optionally substituted methylene protecting group for the N- and O- atoms.
  • A' is wherein R 4 and R 5 are independently C 1-6 alkyl, for example they are both methyl.
  • A' is optionally substituted -CH(Ph)-, preferably A' is -CH(Ph)-.
  • a reaction is performed in an aqueous or mixed aqueous solvent system. Conveniently concentrated hydrochloric acid is used.
  • A' and R 1 are as hereinbefore defined and Q 1 is a displaceable group, and an anion of the formula -OAr wherein Ar is as hereinbefore defined.
  • Q 1 is a sulphonate such as a C 1-6 alkanesulphonate for example methanesulphonate, trifluoromethanesulphonate or an arylsulphonate for example benzenesulphonate or toluene-p-sulphonate, or a phosphonate or phosphinate for example diphenylphosphonate or diphenylphosphinate, or Q 1 is halo for example bromo or chloro.
  • the anion of the formula -OAr is conveniently formed in situ from the corresponding hydroxy compound.
  • the anion of the formula -OAr is conveniently generated by the action of base, for example an alkali metal hydroxide or alkaline earth metal hydroxide, for example sodium hydroxide, or for example an organic base such as triethylamine.
  • base for example an alkali metal hydroxide or alkaline earth metal hydroxide, for example sodium hydroxide, or for example an organic base such as triethylamine.
  • the anion of the formula -OAr is introduced into the reaction as the alkali metal salt of the hydroxy compound, for example the sodium or potassium salt.
  • the reaction between the compound of the formula (IX) and an anion of the formula -OAr is conveniently performed in a substantially inert aprotic solvent such as dimethylformamide.
  • the S-isomers of the compounds of the formula (IX) can be prepared by reacting the S-isomer of a compound of the formula (X) with a compound capable of introducing the group Q 1 :
  • R 1 and A' are as hereinbefore defined.
  • Suitable reagents for introducing the group Q 1 are sulphonylating agents for example methanesulphonyl chloride, benzenesulphonyl chloride and toluene-p-sulphonyl chloride; phosphoryl and phosphinyl reagents for example diphenylphosphoryl chloride and diphenylphosphinyl chloride; and halogenating agents for example thionyl chloride or thionyl bromide, used in conventional manner.
  • sulphonylating agents for example methanesulphonyl chloride, benzenesulphonyl chloride and toluene-p-sulphonyl chloride
  • phosphoryl and phosphinyl reagents for example diphenylphosphoryl chloride and diphenylphosphinyl chloride
  • halogenating agents for example thionyl chloride or thionyl bromide, used in conventional manner.
  • the S-isomers of the compounds of the formula (X) can be prepared in conventional manner by reacting an appropriate precursor, for example a ketone or optionally substituted benzaldehyde, with the S-isomer of a compound of the formula (XI) :
  • R 1 is as hereinbefore defined.
  • the S-isomers of the compounds of the formula (XI) represent another important intermediate and are a further aspect of the invention.
  • R 1 is phenyl.
  • the S-isomers of the compounds of the formula (XI) can be prepared by reacting the S-isomer of a compound of the formula: CHOCH(OH)CH 2 OH with a compound of the formula: R 1 CH 2 NH 2 wherein R 1 is as hereinbefore defined, in the presence of a reducing agent, for example hydrogen and a transition metal catalyst.
  • a reducing agent for example hydrogen and a transition metal catalyst.
  • This mixture was added to a slurry of 5% palladium on carbon (1.5 g) in methanol (40 ml) and hydrogenated at 344 KPa (50 p.s.i.) for 30 minutes.
  • the mixture was filtered, treated with 6N hydrochloric acid (150 ml), distilled until the vapour temperature was 98°C and heated under reflux for one hour.
  • the mixture was cooled, taken to pH 14 with sodium hydroxide, extracted into dichloromethane (3 times), dried and evaporated under reduced pressure to give an oil.
  • Example 5 The product from Example 5 (100 mg) was dissolved in ethanol (10 ml), in the presence of palladium hydroxide on carbon and the mixture hydrogenated at 344 KPa (50 p.s.i.) for 3 hours. Filtration to remove catalyst followed by evaporation of solvent gave a pale oil which was purified by preparative tlc (dichloromethane:methanol (saturated with ammonia) 9:1), to give S-(-)-2-hydroxy-3-[4-(2-(cyclopropylmethoxy)ethyl)phenoxy]-N-isopropylpropylamine, 28.5 mg, identical with an authentic sample by chromatography and a nuclear magnetic resonance spectrum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The S-isomer of a compound of the formula (V), wherein Ar is an optionally substituted aryl, heteroaryl or heterocyclic group, and R1 is phenyl optionally substituted by C1-6alkoxy or C1-6alkyl and its use in a process for the preparation of the S-isomer of compounds of formula (VII), wherein the group R2R3CH- is optionally substituted alkyl.

Description

Stereoselective process and chiral intermediates for Aryloxydropanolamines.
The present invention relates to a general method for preparing chiral β-adrenoceptor antagonists and to intermediates therefor. β-Adrenoceptor antagonists are useful in the treatment of a range of diseases for example hypertension, angina, myocardial infarction, arrhythmias, thyrotoxicosis, anxiety, migraine, tremor, glaucoma and congestive heart failure.
Many β-adrenoceptor antagonists have the general formula (I) :-
Figure imgf000003_0001
wherein Ar is an optionally substituted aryl, heteroaryl or heterocyclic group as known in the art, and R is an optionally substituted alkyl group as known in the art for example a group R2R3CH- as hereinafter defined. The carbon atom bearing the hydroxy group is chiral and it is generally acknowledged that β-adrenoceptor activity resides in the S-isomer. Generally such S-isomers are prepared by resolution or by asymmetric synthesis. However, these processes are difficult and inefficient and, in general, S-isomers of β-adrenoceptor antagonists substantially free of the corresponding R-isomer have not been widely commercialised.
In an asymmetric synthesis known in the art (GB 2130585 A) a compound of the formula (II):
Figure imgf000003_0002
wherein R and Ar are as hereinbefore defined, is treated with to form the compound of the formula (I) . This intermediate compound of the formula (II) is derived from the appropriate isomer of a compound of the formula (III) :
RNHCH2CH(OH)CH2OH (III)
wherein R is as hereinbefore defined, by reaction with benzaldehyde and modification of the terminal hydroxy group to introduce the -O-Ar group.
A wide variety of groups R are known in the β-adrenoceptor antagonist art. Clearly the group R is introduced at a very early stage of the overall asymmetric synthesis. Therefore it is particularly inefficient to synthesise chiral compounds as this necessitates a complete synthetic sequence for each value of R.
It is particularly beneficial to have a general intermediate that can provide a wide range of chiral β-adrenoceptor antagonists with introduction of the group R at a late stage of the synthetic sequence. The present invention provides such an intermediate, additionally this is readily formed in good yields.
Accordingly, the present invention provides the S-isomer of a compound of the formula (IV) :
Figure imgf000004_0001
wherein Ar is an optionally substituted aryl, heteroaryl or heterocyclic group, and R is phenyl optionally substituted by C1-6alkoxy or C1-6alkyl.
In this specification 'S-isomer' relates to the absolute configuration of the pictured carbon atom bearing the hydroxy group; and is preferably provided substantially free of the corresponding R-isomer.
Suitably Ar is an optionally substituted aryl, heteroaryl or heterocyclic group as known in the β-adrenoceptor antagonist art.
More suitably Ar is phenyl optionally substituted by one, two or three groups selected from hydrogen, C1-6alkyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, C2-6alkenyl, C2-6alkenyloxy, C3-10cycloalkyl, halo, carbamoyl, C1-6alkylcarbamoyl, di-C1-6alkylcarbamoyl, arylcarbamoyl, arylC1-6alkyl, arylC1-6alkoxy, C1-6alkanoylamino, arylC1-6alkanoylamino, arylC1-6alkanoyl, arylC2-6alkenyl, carbamoylC1-6alkyl, C1-6alkylcarbamoylC1-6alkyl, di-C1-6alkylcarbamoylC1-6alkyl, aryl, aryloxy, C1-6alkylthio, cyano, hydroxyC1-6alkyl, C1-6alkanoylC1-6alkyl, amino, C1-6alkylamino, di-C1-6alkylamino, morpholino, C3-10cycloalkylC1-6alkoxy, C3-10cycloalkylC1-6alkoxyC1-6alkyl, C3-10cycloalkylC1-6alkoxy-C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, C3-10cycloalkylC1-6alkyl, ureido, C1-6alkylureido, C1-6alkylsulphonamido and arylsulphonamido. Suitably also Ar is indanyl, indenyl, naphthyl, 5-oxotetrahydronaphthyl, 6-oxotetrahydronaphthyl, tetrahydronaphthyl, 5,8-dihydronaphthyl or 7 ,8-dihydroxytetrahydronaphthyl. When Ar is an optionally substituted heteroaryl or heterocyclic group suitably it contains up to three heteroatoms selected from oxygen, sulphur and nitrogen. For example, pyridinyl, pyrimidinyl, quinolinyl, indolyl, and 1,2,5-thiadiazol-3-yl. Suitable substituents, where appropriate, are those described hereinabove as suitable for substitution on phenyl.
Examples of groups Ar are 2-cyanophenyl, 2-methylphenyl, 2,3-dimethylphenyl, 4-(2-methoxyethyl)phenyl, 4-(carbamoylmethyl)phenyl, 2-allyloxy, 4-butyronamidophenyl, 2-chlorophenyl, 2-methoxyphenyl, 2-morpholinophenyl, 4-(2-(cyclopropylmethoxy)ethyl)phenyl, 4-methanesulphonamidophenyl, 4-(2-acetylethyl)phenyl, 4-morpholino1,2,5-thiadiazol-3-yl, 4-acetamidophenyl and phenyl.
Suitably R1 is phenyl or phenyl substituted by one, two or three groups selected from C1-6alkoxy and C1-6alkyl, for example methylphenyl, methoxyphenyl and ethoxyphenyl. Preferably R1 is phenyl.
The compounds of the formula (IV) are useful in that they can be converted to the S-isomers of a wide range of β-adrenoceptor antagonists in two steps.
Accordingly in another aspect the present invention provides a process for preparing the S-isomer of a compound of the formula (V) :
)
Figure imgf000006_0001
where R1 and Ar are as hereinbefore defined, and R2R3CH- represents optionally substituted alkyl: which process comprises reacting the S-isomer of a compound of the formula (IV) as hereinbefore defined with a compound of the formula (VI) , or a compound of the formula (VIA) under conditions of reductive alkylation :
R2R3CH-X (VI) R2R3C=O (VIA)
wherein R2 and R3 are as hereinbefore defined and X is a displaceable group.
In a further aspect the present invention provides the S-isomer of a compound of the formula (V) . Suitable and preferred values for R1 and Ar are as described for compounds of the formula (IV) .
Suitably R2R3CH- is a moiety known in the β-adrenoceptor antagonist art, for example R2 is hydrogen or C1-6alkyl, preferably hydrogen or methyl, and R3 is optionally substituted C1-6alkyl. Suitable substituents for R3 include those of the following sub-formulae:
i) Ra-O-C(=O)-
ii) Ra-CO-NH-
iii) Ra-NRb-CO-
iv) Ra-NRb-CO-NH-
wherein Ra is C1-6alkyl, phenyl or phenylC1-6alkyl, said phenyl groups being optionally substituted by one, two or three groups as defined hereinabove with reference to suitable substituents for Ar; and Rb is hydrogen or C1-6alkyl. Preferably R2R3CH- is isopropyl. The reaction between compounds of the formulae (IV) and (VI) is performed in conventional manner. Suitably X is halo, for example chloro or bromo. Conveniently the reaction is performed in a substantially inert solvent.
The reaction between compounds of the formulae (IV) and (VIA) is performed under conventional reductive alkylation conditions, for example in a substantially inert solvent in the presence of Raney nickel.
In another aspect the present invention provides a process for the preparation of the S-isomer of a compound of the formula (VII) :
Figure imgf000008_0001
wherein R2 , R3 and Ar are as hereinbefore defined, which comprises reducing the S-isomer of a compound of the formula (V) as hereinbefore defined.
Suitably the reduction is performed using catalytic hydrogenation in conventional manner. For example using conventional transition metal catalysts such as palladium on a suitable carrier with hydrogen gas or under conditions of catalytic transfer hydrogenation. For example palladium on carbon and palladium hydroxide on carbon may be used. Hydrogenation with hydrogen gas may be performed at non-extreme pressure for example between atmospheric pressure and pressures of 10 atmospheres. Suitably hydrogenation is performed in a C1-4alkanol for example ethanol. Catalytic transfer hydrogenation can be effected for example using hydrazine.
The S-isomers of the compounds of the formula (IV) as hereinbefore defined can be prepared by reacting the
S-isomer of a compound of the formula (VIII) with acid:
Figure imgf000009_0002
wherein R1 and Ar are as hereinbefore defined, and A' is an acid-cleavable optionally substituted methylene protecting group for the N- and O- atoms.
Suitably A' is wherein
Figure imgf000009_0003
R4 and R5 are independently C1-6alkyl, for example they are both methyl. Suitably also A' is optionally substituted -CH(Ph)-, preferably A' is -CH(Ph)-. Suitably such a reaction is performed in an aqueous or mixed aqueous solvent system. Conveniently concentrated hydrochloric acid is used.
The S-isomers of the compounds of the formula (VIII) are conveniently prepared from the S-isomer of a compound of the formula (IX) :
Figure imgf000009_0001
wherein A' and R1 are as hereinbefore defined and Q1 is a displaceable group, and an anion of the formula -OAr wherein Ar is as hereinbefore defined.
In the compounds of the formula (IX) suitably Q1 is a sulphonate such as a C1-6alkanesulphonate for example methanesulphonate, trifluoromethanesulphonate or an arylsulphonate for example benzenesulphonate or toluene-p-sulphonate, or a phosphonate or phosphinate for example diphenylphosphonate or diphenylphosphinate, or Q1 is halo for example bromo or chloro. The anion of the formula -OAr is conveniently formed in situ from the corresponding hydroxy compound. The anion of the formula -OAr is conveniently generated by the action of base, for example an alkali metal hydroxide or alkaline earth metal hydroxide, for example sodium hydroxide, or for example an organic base such as triethylamine. In a suitable alternative the anion of the formula -OAr is introduced into the reaction as the alkali metal salt of the hydroxy compound, for example the sodium or potassium salt. The reaction between the compound of the formula (IX) and an anion of the formula -OAr is conveniently performed in a substantially inert aprotic solvent such as dimethylformamide.
The S-isomers of the compounds of the formula (IX) can be prepared by reacting the S-isomer of a compound of the formula (X) with a compound capable of introducing the group Q1 :
Figure imgf000010_0001
wherein R1 and A' are as hereinbefore defined.
Suitable reagents for introducing the group Q1 are sulphonylating agents for example methanesulphonyl chloride, benzenesulphonyl chloride and toluene-p-sulphonyl chloride; phosphoryl and phosphinyl reagents for example diphenylphosphoryl chloride and diphenylphosphinyl chloride; and halogenating agents for example thionyl chloride or thionyl bromide, used in conventional manner.
The S-isomers of the compounds of the formula (X) can be prepared in conventional manner by reacting an appropriate precursor, for example a ketone or optionally substituted benzaldehyde, with the S-isomer of a compound of the formula (XI) :
Figure imgf000011_0001
wherein R1 is as hereinbefore defined.
The S-isomers of the compounds of the formula (XI) represent another important intermediate and are a further aspect of the invention. Preferably in such compounds R1 is phenyl.
The S-isomers of the compounds of the formula (XI) can be prepared by reacting the S-isomer of a compound of the formula: CHOCH(OH)CH2OH with a compound of the formula: R1CH2NH2 wherein R1 is as hereinbefore defined, in the presence of a reducing agent, for example hydrogen and a transition metal catalyst.
The following Examples illustrate the invention,
Example 1
To a stirred suspension of mannitol diacetonide (26.2 g) in benzene (800 ml) was added lead tetraacetate (44.2 g) over 5 minutes. The resultant solid was broken up to give a cloudy solution, stirred for 45 minutes, filtered, evaporated under reduced pressure and distilled to give as an oil, acetone-d-glyceraldehyde (17.7 g) , b.p. 44-8°C/11 mm Hg. To a solution of this in methanol (60 ml), at 5°C, was added slowly a solution of benzylamine (10.7 g) in methanol (60 ml). This mixture was added to a slurry of 5% palladium on carbon (1.5 g) in methanol (40 ml) and hydrogenated at 344 KPa (50 p.s.i.) for 30 minutes. The mixture was filtered, treated with 6N hydrochloric acid (150 ml), distilled until the vapour temperature was 98°C and heated under reflux for one hour. The mixture was cooled, taken to pH 14 with sodium hydroxide, extracted into dichloromethane (3 times), dried and evaporated under reduced pressure to give an oil. This oil was extracted with boiling ether (twice), filtered whilst warm and on standing gave as a crystalline solid (S) - (-) -3-benzylamino-1,2-propanediol (10.1 g) , [ α]2 D 5 = -25.72° [concentration 1.01% in ethanol : water: concentrated HCl (17:2:1)], m.p. 63°C.
Example 2
Part of the product from Example 1 (7.24 g) in warm toluene (35 ml) and benzaldehyde (4.66 g) were stirred at room temperature for 90 minutes, then stirred under reflux for 60 minutes removing water using a Dean-Stark apparatus. The solution was then cooled, evaporated under reduced pressure to give an oil which was crystallised from ethyl acetate to give (S) - (-) -2-phenyl-3-benzyl-5-hydroxymethyloxazolidine (8.1 g) , m.p. 100°C.
Example 3
Part of the product from Example 2 (6.73 g) in pyridine (10 ml) and toluene-p-sulphonyl chloride (4.8 g) were stirred at room temperature for 2 hours (initial cooling). Potassium carbonate (4.13 g) in water (20 ml) was added cautiously and the product extracted into dichloromethane (3 times). The organic extracts were dried and evaporated under reduced pressure to give the tosylate (10.7 g) as an oil. The tosylate in dimethylformamide (12.5 ml) was added in portions to a solution of the anion of 4- (2- (cyclopropylmethoxy)ethyl)phenol (4.8 g) (formed from sodium hydride (50% dispersion; 1.25 g)) in dimethylformamide (12.5 ml). The reaction mixture was heated at 70°C for 6 hours, poured on to ice (90 g) and extracted into ether (3 times). The ether extracts were washed with water, dried and evaporated to give (S)-(-)-2-phenyl-3-benzyl-5-(4-(2-cyclopropylmethylmethoxy)ethyl)phenoxymethyl)oxazolidine as an orange oil (9.78 g) .
Example 4
The oxazolidine from Example 3 (9.78 g) was slurried in a mixture of water (80 ml) and concentrated hydrochloric acid (20 ml) for one hour until the orange oil had changed to a pale yellow solid. The solid was filtered, washed with water, slurried with ether, filtered and dried under vacuum to give (S) - (-) -2-hydroxy-3-[4-(2-(cyclopropylmethoxy)ethyl)phenoxy]-N-benzylpropylamine as a hydrochloride (5.18 g) , m.p. 172°C (recrystallisation from acetonitrile) , [α]2 D 5 = -14.0° [concentration 1.11% in ethanol : water: concentrated HCl (17:2:1)], m.p. 172°C.
Example 5
S-(-)-2-Hydroxy-3-[4-(2-(cyclopropylmethoxy)ethyl)-phenoxy]-N-benzylpropylamine (1.77 g) and isopropyl iodide (0.98 g) were heated under reflux in ethanol (20 ml) for 12 hours. Ethanol was removed under reduced pressure, the resultant oil dissolved in dichloromethane (20 ml), washed with base (NaOH solution, pH 14, 20 ml), separated, dried (MgSO4) , filtered and evaporated to give a pale brown oil. Column chromatography (silica gel: methanol: dichloromethane 1:9) gave S-(-)-2-hydroxy-3-[4-(2- (cyclopropylmethoxy)ethyl)phenoxy]-N-benzyl-N'-isopropylpropylamine as a pale oil (120 mg) ; (CDCl3) 7.30 (5H,m, PhCH2N) , 3.90 (2H,m,PhCH2N) , 3.60 (2H,m,CH(OH)-CH2O-) , 2.98 (1H ,m,NCH(CH3)2) , 2.60 (2H,m,NCH2CH(OH)) , 1.07 (3H,d,NCH(CH3)2) , 1,01 (3H,d,NH(CH3)2) , ppm. Example 6
The product from Example 5 (100 mg) was dissolved in ethanol (10 ml), in the presence of palladium hydroxide on carbon and the mixture hydrogenated at 344 KPa (50 p.s.i.) for 3 hours. Filtration to remove catalyst followed by evaporation of solvent gave a pale oil which was purified by preparative tlc (dichloromethane:methanol (saturated with ammonia) 9:1), to give S-(-)-2-hydroxy-3-[4-(2-(cyclopropylmethoxy)ethyl)phenoxy]-N-isopropylpropylamine, 28.5 mg, identical with an authentic sample by chromatography and a nuclear magnetic resonance spectrum.

Claims

Claims :
1. A compound of the formula:
Figure imgf000015_0001
wherein R1 is phenyl optionally substituted by C1-6alkoxy or C1-6alkyl, and Ar is an optionally substituted aryl, heteroaryl or heterocyclic group: in the form of the S-isomer.
2. A compound of the formula
Figure imgf000015_0002
where R1 is phenyl optionally substituted by C1-6alkoxy or C1-6alkyl, R2R3CH- is optionally substituted alkyl and Ar is an optionally substituted aryl, heteroaryl or heterocyclic group: in the form of the S-isomer.
3. A compound according to claim 1 or claim 2 wherein R1 is phenyl.
4. A compound according to claim 2 or 3 wherein R2R3CH- is isopropyl.
5. A process for preparing the S-isomer of a compound of the formula (VII) : o o
Figure imgf000015_0003
wherein R2 , R3 and Ar are as defined in claim 1, which comprises reducing the S-isomer of a compound of the formula (V) :
Figure imgf000016_0003
wherein R2 , R3 , Ar and R1 are as defined in claim 2.
6. A process for preparing the S-isomer of a compound of the formula (V) as defined in claim 2 which comprises reacting the S-isomer of a compound of the formula (IV):
Figure imgf000016_0002
wherein R and Ar are as defined in claim 2, with a compound of the formula (VI) , or with a compound of the formula (VIA) under conditions of reductive alkylation:
R2R3CH-X (VI ) R2R3C=O (VIA)
wherein R2 and R3 are as defined in claim 2 and X is a displaceable group.
7. A compound of the formula (XI) :
Figure imgf000016_0001
wherein R1 is as defined in claim 1: in the form of the S-isomer.
8. A compound according to claim 7 wherein R1 is phenyl.
PCT/GB1985/000514 1985-04-20 1985-11-12 Stereoselective process and chiral intermediates for aryloxydropanolamines WO1986006368A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT85905641T ATE40548T1 (en) 1985-04-20 1985-11-12 STEREOSELECTIVE PROCESS AND CHIRAL INTERMEDIATE PRODUCTS FOR ARYLOXYPROPANOLAMINE.
DE8585905641T DE3568040D1 (en) 1985-04-20 1985-11-12 Stereoselective process and chiral intermediates for aryloxydropanolamines
DK619886A DK619886D0 (en) 1985-04-20 1986-12-19 BETA-ADRENOCEPTOR ANTAGONISTS AND THE PREPARATION OF IT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858510146A GB8510146D0 (en) 1985-04-20 1985-04-20 Chemical compounds & processes
GB8510146 1985-04-20

Publications (1)

Publication Number Publication Date
WO1986006368A1 true WO1986006368A1 (en) 1986-11-06

Family

ID=10577964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1985/000514 WO1986006368A1 (en) 1985-04-20 1985-11-12 Stereoselective process and chiral intermediates for aryloxydropanolamines

Country Status (10)

Country Link
EP (1) EP0219505B1 (en)
JP (1) JPS62502963A (en)
AU (1) AU573931B2 (en)
DE (1) DE3568040D1 (en)
ES (1) ES8704447A1 (en)
GB (1) GB8510146D0 (en)
GR (1) GR852744B (en)
PT (1) PT81419B (en)
WO (1) WO1986006368A1 (en)
ZA (1) ZA858363B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
AU627052B2 (en) * 1990-07-27 1992-08-13 Zeneca Limited Phenyl ethers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines
GB1591723A (en) * 1976-10-05 1981-06-24 Ciba Geigy Ag 1-amino-2-hydroxy-3-heterocyclyloxy-propanes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2512443A1 (en) * 1981-09-10 1983-03-11 Synthelabo PHENOXY-3 PROPANOL-2 DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1591723A (en) * 1976-10-05 1981-06-24 Ciba Geigy Ag 1-amino-2-hydroxy-3-heterocyclyloxy-propanes
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines

Also Published As

Publication number Publication date
JPS62502963A (en) 1987-11-26
GB8510146D0 (en) 1985-05-30
AU5067385A (en) 1986-11-18
ES548863A0 (en) 1987-04-01
AU573931B2 (en) 1988-06-23
EP0219505B1 (en) 1989-02-01
GR852744B (en) 1986-03-14
ES8704447A1 (en) 1987-04-01
EP0219505A1 (en) 1987-04-29
PT81419B (en) 1987-10-01
PT81419A (en) 1985-11-01
ZA858363B (en) 1987-06-24
DE3568040D1 (en) 1989-03-09

Similar Documents

Publication Publication Date Title
Cardellicchio et al. The Betti base: absolute configuration and routes to a family of related chiral nonracemic bases
US5225585A (en) Production of fluoxetine and new intermediates
CZ20022255A3 (en) Process for preparing tolterodine and analogs thereof as well as intermediates prepared thereby
EP2155684B1 (en) Process for producing cisatracurium compounds and associated intermediates
US5633404A (en) N-((R)-α-methyl-3-methoxybenzyl)-3-(2-chlorobenzene)propanamide
US6015903A (en) Method of resolving racemic mixtures
EP0909754A1 (en) Process to make chiral compounds
US5468746A (en) Compounds active on the cardiovascular system
EP0828711B1 (en) New process for the preparation of ropivacaine hydrochloride monohydrate
AU573931B2 (en) Stereoselective process and chiral intermediates for aryloxydropanolamines
RU2265595C2 (en) Method for preparing(-)-cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine and intermediates compounds
GB1575800A (en) Spiro amines their production and compositions containing them
Adamo et al. An Improved Resolution Of 2-Methyl Piperidine And Its Use in The Synthesis Of Homochiral Trans-2, 6-Dialkyl Piperidines
US4659833A (en) Optically active isocarbostyril derivatives and a method of preparing the same
US6127362A (en) 9,10-diazatricyclo[4,4,1,12,5 ] decane and 2,7-diazatricyclo [4,4,0,03,8 ] decane derivatives having analgesic activity
EP0129383B1 (en) Process for the preparation of 3,4-di-isobutyryloxy-n-methyl-phenethylamine
US4585894A (en) Process for producing 9-carbamoyl fluorene derivatives
US4501891A (en) Method of forming a solution of papavrine carbanion
AU1729697A (en) Racemisation of quaternary chiral centers
US4387230A (en) Process for preparing a dihydropyridine derivative
US5468876A (en) Intermediates for the stereoconservative synthesis of 1-substituted (S)-and (R)-2-aminomethylpyrrolidines
SU1240354A3 (en) Method of producing pyrbuterol dihydrochloride
CA1187490A (en) Process for the production of ketoamines
JPS60146852A (en) Propanolamine derivative
EP0274409A2 (en) Process for preparing alkoxyalkyl-idenehydrazinopyridazine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985905641

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985905641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1985905641

Country of ref document: EP